SlideShare une entreprise Scribd logo
1  sur  69
Télécharger pour lire hors ligne
Hematology – Highyield Topics
[object Object]
Abnormal Blood Flow Abnormal Vessel Wall Dr. Rudolph Virchow 1821-1902 The Hypercoagulable State Abnormal Blood
Thrombosis Hereditary thrombophilia Acquired thrombophilia Surgery trauma Immobility Inflammation Malignancy Estrogens Atherosclerosis
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
FXI   FIX FXII FV FVII Prothrombin Thrombin Fibrinogen Fibrin Clot FVIII FX
J Thromb. Haem.1.525, 2003
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
 
 
 
 
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object]
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
APPROACH
 
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Patient characteristics Risk of recurrence (%) - In the year after discontinuation Duration of Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],3% <10% if risk factor avoided. >10% if persistent <10% >10% >10% >10% 3 months 6 months Until factor resolves 6 months Indefinite Indefinite Indefinite. Consider long term Rx with LMWH in pts with cancer
Diagnosis Management
[object Object],[object Object],[object Object],[object Object]
.
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],HIT
[object Object],[object Object],[object Object],[object Object]
Sequelae Incidence Thrombosis 30%–50%  Amputation 20% (arterial thrombosis) Death 22% to 28% .
[object Object],4:1 Incidence Ratio Venous to Arterial Arterial Aortic/Ileofemoral Thrombosis Acute Thrombotic Stroke  Myocardial Infarction, Mural thrombosis, Thrombi in upper limb, mesenteric, renal and spinal arts. Venous  Deep Vein Thrombosis Pulmonary Embolism Cerebral Dural  Sinus Thrombosis Adrenal Hemorrhagic Infarction
HIT Temporal Variants Day 1 Day 4 Day 14 Day 30 Delayed-onset  HIT  (9–40 days) Rapid-onset HIT  (hours–days) Typical HIT Mean Day 9 (5–14 days) Heparin (re) Exposure THROMBOCYTOPENIA (± THROMBOSIS)
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],There is no Gold Standard in diagnostic testing; HIT requires a clinical diagnosis .
[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Indications Argatroban FDA-approved for HIT  (also for PCI)  Lepirudin FDA-approved for HIT Bivalirudin (Angiomax) PCI (including HIT patients) Fondaparinux  (Arixtra) FDA approved for DVT Prophylaxis in patients with Hip#, Hip or knee replacements. Also used in Rx of  VTE. Not yet approved for HIT (Off-label use) Danaparoid Approved for HIT in Canada, Europe, Aust.
[object Object],[object Object],[object Object],[object Object],[object Object]
HIT Patients HIT Patients with Renal Impairment HIT Patients with Hepatic Impairment * Not to exceed a dose of 10 µg/kg/min or aPTT of 100 seconds † Due to approximate 4-fold decrease in Argatroban clearance relative to those with normal hepatic function Initiate at  2 µg/kg/min Titrate until steady-state aPTT is 1.5–3.0 times baseline value* No dosage adjustment required Initiate at  0.5 µg/kg/min † Titrate until steady-state aPTT is 1.5–3.0 times baseline value*
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
If INR is below the therapeutic range for warfarin alone, resume Argatroban therapy  If INR is >4.0, stop Argatroban infusion Initiate warfarin therapy using the expected  daily dose of warfarin while maintaining Argatroban infusion. *  A loading dose of warfarin should not be used If INR is within therapeutic range on warfarin alone, continue warfarin monotherapy If INR is   4.0, continue concomitant therapy Repeat INR 4-6 hours later Measure INR daily *  For Argatroban infusion at   2 µg/kg/min, the INR on monotherapy may be estimated from the INR on cotherapy. If the dose of Argatroban >2   g/kg/min, temporarily reduce to a dose of 2   g/kg/min 4-6 hours prior to measuring the INR.  
[object Object],[object Object],[object Object],Consider HIT during/soon after heparin exposure* *  Heparin exposure may be through virtually any preparation (including LMWH), any dose, or any route of heparin (including flushes and coated lines)
Questions?

Contenu connexe

Tendances

Platelet function tests.pptx 2.pptx final
Platelet function tests.pptx 2.pptx finalPlatelet function tests.pptx 2.pptx final
Platelet function tests.pptx 2.pptx finalAnupam Singh
 
Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...
Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...
Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...Chetan Ganteppanavar
 
An approach to a patient with Thrombocytopenia
An approach to a patient with ThrombocytopeniaAn approach to a patient with Thrombocytopenia
An approach to a patient with Thrombocytopeniaaminanurnova
 
Autoimmune Hemolytic Anemia (AIHA)
Autoimmune Hemolytic Anemia (AIHA)Autoimmune Hemolytic Anemia (AIHA)
Autoimmune Hemolytic Anemia (AIHA)RGCL
 
Anti phospholipid antibody ppt
Anti phospholipid antibody pptAnti phospholipid antibody ppt
Anti phospholipid antibody pptJyoti Sharma
 
Inherited bleeding disorders
Inherited bleeding disordersInherited bleeding disorders
Inherited bleeding disordersbrijendra72u
 
ANTINUCLEAR ANTIBODY
ANTINUCLEAR  ANTIBODYANTINUCLEAR  ANTIBODY
ANTINUCLEAR ANTIBODYMusa Khan
 
Glanzmann thrombasthenia
Glanzmann thrombastheniaGlanzmann thrombasthenia
Glanzmann thrombastheniavijay dihora
 
Platelet Function Tests
Platelet Function TestsPlatelet Function Tests
Platelet Function TestsAhmed Makboul
 
Laboratory Approach to coagulation disorders & Mixing studies
Laboratory Approach to coagulation disorders & Mixing studiesLaboratory Approach to coagulation disorders & Mixing studies
Laboratory Approach to coagulation disorders & Mixing studiesSUNIL KUMAR PEDDANA
 
Approach to Hemolytic Anemia
Approach to Hemolytic AnemiaApproach to Hemolytic Anemia
Approach to Hemolytic AnemiaAbdullah Ansari
 
Refreactory anemia
Refreactory anemiaRefreactory anemia
Refreactory anemiaariva zhagan
 
Bleeding disorders(Disorders of Platelets and vessel wall)
Bleeding disorders(Disorders of Platelets and vessel wall)Bleeding disorders(Disorders of Platelets and vessel wall)
Bleeding disorders(Disorders of Platelets and vessel wall)Rajesh S
 

Tendances (20)

Platelet function tests.pptx 2.pptx final
Platelet function tests.pptx 2.pptx finalPlatelet function tests.pptx 2.pptx final
Platelet function tests.pptx 2.pptx final
 
APPROACH TO PANCYTOPENIA
APPROACH TO PANCYTOPENIA APPROACH TO PANCYTOPENIA
APPROACH TO PANCYTOPENIA
 
Hemolytic anemia ppt presentation
Hemolytic anemia ppt presentationHemolytic anemia ppt presentation
Hemolytic anemia ppt presentation
 
Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...
Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...
Sideroblastic anemia - Etiopathogenesis, Clinical features, Advances in Manag...
 
An approach to a patient with Thrombocytopenia
An approach to a patient with ThrombocytopeniaAn approach to a patient with Thrombocytopenia
An approach to a patient with Thrombocytopenia
 
Autoimmune Hemolytic Anemia (AIHA)
Autoimmune Hemolytic Anemia (AIHA)Autoimmune Hemolytic Anemia (AIHA)
Autoimmune Hemolytic Anemia (AIHA)
 
Anti phospholipid antibody ppt
Anti phospholipid antibody pptAnti phospholipid antibody ppt
Anti phospholipid antibody ppt
 
Inherited bleeding disorders
Inherited bleeding disordersInherited bleeding disorders
Inherited bleeding disorders
 
ANTINUCLEAR ANTIBODY
ANTINUCLEAR  ANTIBODYANTINUCLEAR  ANTIBODY
ANTINUCLEAR ANTIBODY
 
Glanzmann thrombasthenia
Glanzmann thrombastheniaGlanzmann thrombasthenia
Glanzmann thrombasthenia
 
Platelet Function Tests
Platelet Function TestsPlatelet Function Tests
Platelet Function Tests
 
Laboratory Approach to coagulation disorders & Mixing studies
Laboratory Approach to coagulation disorders & Mixing studiesLaboratory Approach to coagulation disorders & Mixing studies
Laboratory Approach to coagulation disorders & Mixing studies
 
Approach to Hemolytic Anemia
Approach to Hemolytic AnemiaApproach to Hemolytic Anemia
Approach to Hemolytic Anemia
 
Myelodysplastic syndrome
Myelodysplastic syndromeMyelodysplastic syndrome
Myelodysplastic syndrome
 
TTP HUS
TTP HUSTTP HUS
TTP HUS
 
Approach to pancytopenia
Approach to pancytopeniaApproach to pancytopenia
Approach to pancytopenia
 
approach to MPN
approach to MPNapproach to MPN
approach to MPN
 
Refreactory anemia
Refreactory anemiaRefreactory anemia
Refreactory anemia
 
Approach to thrombocytopenia.pptx
Approach to  thrombocytopenia.pptxApproach to  thrombocytopenia.pptx
Approach to thrombocytopenia.pptx
 
Bleeding disorders(Disorders of Platelets and vessel wall)
Bleeding disorders(Disorders of Platelets and vessel wall)Bleeding disorders(Disorders of Platelets and vessel wall)
Bleeding disorders(Disorders of Platelets and vessel wall)
 

Similaire à Thrombophilias

thrombophilias2-111216175316-phpapp02.pdf
thrombophilias2-111216175316-phpapp02.pdfthrombophilias2-111216175316-phpapp02.pdf
thrombophilias2-111216175316-phpapp02.pdfHaematologyCenterRep
 
Hypercoagulable state.pptx
Hypercoagulable state.pptxHypercoagulable state.pptx
Hypercoagulable state.pptxKIRANGEORGEN
 
thromboticdisorders-150818135124-lva1-app6892.pdf
thromboticdisorders-150818135124-lva1-app6892.pdfthromboticdisorders-150818135124-lva1-app6892.pdf
thromboticdisorders-150818135124-lva1-app6892.pdfmergawekwaya
 
Antiphospholipid syndrome By Dr.Rozan
Antiphospholipid syndrome By Dr.RozanAntiphospholipid syndrome By Dr.Rozan
Antiphospholipid syndrome By Dr.RozanRafi Rozan
 
Bleeding disorders in pregnancy
Bleeding disorders in pregnancyBleeding disorders in pregnancy
Bleeding disorders in pregnancydrmcbansal
 
Hereditary and acquired thrombophilia in RIF & recurrent abortion
Hereditary and acquired thrombophilia in RIF & recurrent abortionHereditary and acquired thrombophilia in RIF & recurrent abortion
Hereditary and acquired thrombophilia in RIF & recurrent abortionAmir Abbas Hedayati Asl
 
Hematology Rivas2008 Lecture4&5
Hematology Rivas2008 Lecture4&5Hematology Rivas2008 Lecture4&5
Hematology Rivas2008 Lecture4&5Miami Dade
 
Bleeding and Thrombotic Disorders
Bleeding and Thrombotic Disorders Bleeding and Thrombotic Disorders
Bleeding and Thrombotic Disorders Rakesh Verma
 
Antiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx newAntiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx newMohammed Khalil
 
Pathology hematology 3
Pathology   hematology 3Pathology   hematology 3
Pathology hematology 3MBBS IMS MSU
 
The hypercoagulable states in anaesthesia
The hypercoagulable states in anaesthesiaThe hypercoagulable states in anaesthesia
The hypercoagulable states in anaesthesiaSiddhanta Choudhury
 
Thromboembolism 7- 5-15
Thromboembolism 7- 5-15Thromboembolism 7- 5-15
Thromboembolism 7- 5-15Md. Shameem
 
Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)student
 
medicine.Bleeding disorders.(dr.sabir) (new powerpoint)
medicine.Bleeding disorders.(dr.sabir) (new powerpoint)medicine.Bleeding disorders.(dr.sabir) (new powerpoint)
medicine.Bleeding disorders.(dr.sabir) (new powerpoint)student
 
Antiphospholipid syndrome
Antiphospholipid syndromeAntiphospholipid syndrome
Antiphospholipid syndromeAnna Rudaja
 
thrombophilia liu 2014.pdf
thrombophilia liu 2014.pdfthrombophilia liu 2014.pdf
thrombophilia liu 2014.pdfMarcFoster14
 
Hematology lect 3
Hematology lect 3Hematology lect 3
Hematology lect 3Miami Dade
 
Antiphospholipid antibody syndrome
Antiphospholipid antibody syndromeAntiphospholipid antibody syndrome
Antiphospholipid antibody syndromeDimi Laloo
 

Similaire à Thrombophilias (20)

thrombophilias2-111216175316-phpapp02.pdf
thrombophilias2-111216175316-phpapp02.pdfthrombophilias2-111216175316-phpapp02.pdf
thrombophilias2-111216175316-phpapp02.pdf
 
Hypercoagulable state.pptx
Hypercoagulable state.pptxHypercoagulable state.pptx
Hypercoagulable state.pptx
 
thromboticdisorders-150818135124-lva1-app6892.pdf
thromboticdisorders-150818135124-lva1-app6892.pdfthromboticdisorders-150818135124-lva1-app6892.pdf
thromboticdisorders-150818135124-lva1-app6892.pdf
 
Thrombotic disorders
Thrombotic disordersThrombotic disorders
Thrombotic disorders
 
Antiphospholipid syndrome By Dr.Rozan
Antiphospholipid syndrome By Dr.RozanAntiphospholipid syndrome By Dr.Rozan
Antiphospholipid syndrome By Dr.Rozan
 
Bleeding disorders in pregnancy
Bleeding disorders in pregnancyBleeding disorders in pregnancy
Bleeding disorders in pregnancy
 
Hereditary and acquired thrombophilia in RIF & recurrent abortion
Hereditary and acquired thrombophilia in RIF & recurrent abortionHereditary and acquired thrombophilia in RIF & recurrent abortion
Hereditary and acquired thrombophilia in RIF & recurrent abortion
 
Hematology Rivas2008 Lecture4&5
Hematology Rivas2008 Lecture4&5Hematology Rivas2008 Lecture4&5
Hematology Rivas2008 Lecture4&5
 
Bleeding and Thrombotic Disorders
Bleeding and Thrombotic Disorders Bleeding and Thrombotic Disorders
Bleeding and Thrombotic Disorders
 
Antiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx newAntiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx new
 
Pathology hematology 3
Pathology   hematology 3Pathology   hematology 3
Pathology hematology 3
 
The hypercoagulable states in anaesthesia
The hypercoagulable states in anaesthesiaThe hypercoagulable states in anaesthesia
The hypercoagulable states in anaesthesia
 
Thromboembolism 7- 5-15
Thromboembolism 7- 5-15Thromboembolism 7- 5-15
Thromboembolism 7- 5-15
 
Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)Medicine.Bleeding disorders.(dr.sabir)
Medicine.Bleeding disorders.(dr.sabir)
 
medicine.Bleeding disorders.(dr.sabir) (new powerpoint)
medicine.Bleeding disorders.(dr.sabir) (new powerpoint)medicine.Bleeding disorders.(dr.sabir) (new powerpoint)
medicine.Bleeding disorders.(dr.sabir) (new powerpoint)
 
Antiphospholipid syndrome
Antiphospholipid syndromeAntiphospholipid syndrome
Antiphospholipid syndrome
 
COA
COACOA
COA
 
thrombophilia liu 2014.pdf
thrombophilia liu 2014.pdfthrombophilia liu 2014.pdf
thrombophilia liu 2014.pdf
 
Hematology lect 3
Hematology lect 3Hematology lect 3
Hematology lect 3
 
Antiphospholipid antibody syndrome
Antiphospholipid antibody syndromeAntiphospholipid antibody syndrome
Antiphospholipid antibody syndrome
 

Plus de Archer Review USMLE and NCLEX

Safety and infection control - Archer NCLEX webinars
Safety and infection control - Archer NCLEX webinarsSafety and infection control - Archer NCLEX webinars
Safety and infection control - Archer NCLEX webinarsArcher Review USMLE and NCLEX
 
Archer NCLEX Webinars - Diets and Nutrition crash course
Archer NCLEX Webinars - Diets and Nutrition crash courseArcher NCLEX Webinars - Diets and Nutrition crash course
Archer NCLEX Webinars - Diets and Nutrition crash courseArcher Review USMLE and NCLEX
 
Archer NCLEX Rapid Review - Full Content Syllabus - Two days
Archer NCLEX Rapid Review - Full Content Syllabus - Two daysArcher NCLEX Rapid Review - Full Content Syllabus - Two days
Archer NCLEX Rapid Review - Full Content Syllabus - Two daysArcher Review USMLE and NCLEX
 
Cardiology and EKGs - Archer NCLEX crash course/ webinar
Cardiology and EKGs - Archer NCLEX crash course/ webinarCardiology and EKGs - Archer NCLEX crash course/ webinar
Cardiology and EKGs - Archer NCLEX crash course/ webinarArcher Review USMLE and NCLEX
 
Fluids and electrolytes Archer NCLEX content review webinar
Fluids and electrolytes  Archer NCLEX content review webinarFluids and electrolytes  Archer NCLEX content review webinar
Fluids and electrolytes Archer NCLEX content review webinarArcher Review USMLE and NCLEX
 
Infectious disease Archer USMLE Step3 Review Lectures
Infectious disease   Archer USMLE Step3 Review LecturesInfectious disease   Archer USMLE Step3 Review Lectures
Infectious disease Archer USMLE Step3 Review LecturesArcher Review USMLE and NCLEX
 

Plus de Archer Review USMLE and NCLEX (20)

Endocrine Archer NCLEX course Webinar
Endocrine Archer NCLEX course WebinarEndocrine Archer NCLEX course Webinar
Endocrine Archer NCLEX course Webinar
 
Safety and infection control - Archer NCLEX webinars
Safety and infection control - Archer NCLEX webinarsSafety and infection control - Archer NCLEX webinars
Safety and infection control - Archer NCLEX webinars
 
Archer NCLEX Webinars - Diets and Nutrition crash course
Archer NCLEX Webinars - Diets and Nutrition crash courseArcher NCLEX Webinars - Diets and Nutrition crash course
Archer NCLEX Webinars - Diets and Nutrition crash course
 
Rapid Content Prep - NCLEX- Archer Review
Rapid Content Prep - NCLEX- Archer ReviewRapid Content Prep - NCLEX- Archer Review
Rapid Content Prep - NCLEX- Archer Review
 
Archer NCLEX Rapid Review - Full Content Syllabus - Two days
Archer NCLEX Rapid Review - Full Content Syllabus - Two daysArcher NCLEX Rapid Review - Full Content Syllabus - Two days
Archer NCLEX Rapid Review - Full Content Syllabus - Two days
 
Cardiology and EKGs - Archer NCLEX crash course/ webinar
Cardiology and EKGs - Archer NCLEX crash course/ webinarCardiology and EKGs - Archer NCLEX crash course/ webinar
Cardiology and EKGs - Archer NCLEX crash course/ webinar
 
Fluids and electrolytes Archer NCLEX content review webinar
Fluids and electrolytes  Archer NCLEX content review webinarFluids and electrolytes  Archer NCLEX content review webinar
Fluids and electrolytes Archer NCLEX content review webinar
 
Archer NCLEX Pharmacology crash course - Webinar
Archer NCLEX Pharmacology crash course - WebinarArcher NCLEX Pharmacology crash course - Webinar
Archer NCLEX Pharmacology crash course - Webinar
 
Archer NCLEX Review - Electrolyte imbalances
Archer NCLEX Review - Electrolyte imbalancesArcher NCLEX Review - Electrolyte imbalances
Archer NCLEX Review - Electrolyte imbalances
 
Archer USMLE Step 3 Nephrology 2019
Archer USMLE Step 3 Nephrology 2019Archer USMLE Step 3 Nephrology 2019
Archer USMLE Step 3 Nephrology 2019
 
Pulmonology critical care- archer step3 lectures
Pulmonology  critical care- archer step3 lecturesPulmonology  critical care- archer step3 lectures
Pulmonology critical care- archer step3 lectures
 
Endocrinology archer step3 lectures
Endocrinology   archer step3 lecturesEndocrinology   archer step3 lectures
Endocrinology archer step3 lectures
 
Infectious disease Archer USMLE Step3 Review Lectures
Infectious disease   Archer USMLE Step3 Review LecturesInfectious disease   Archer USMLE Step3 Review Lectures
Infectious disease Archer USMLE Step3 Review Lectures
 
Archer step 3 ccs workshop 2019
Archer step 3 ccs workshop 2019Archer step 3 ccs workshop 2019
Archer step 3 ccs workshop 2019
 
Archer USMLE Step 3 CCS workshop 2018
Archer USMLE Step 3 CCS workshop 2018Archer USMLE Step 3 CCS workshop 2018
Archer USMLE Step 3 CCS workshop 2018
 
Cutaneous lymphomas
Cutaneous lymphomasCutaneous lymphomas
Cutaneous lymphomas
 
Acute Lymphoblastic Lymphoma
Acute Lymphoblastic LymphomaAcute Lymphoblastic Lymphoma
Acute Lymphoblastic Lymphoma
 
Gastroenterology
Gastroenterology Gastroenterology
Gastroenterology
 
Carcinoma of unknown primary
Carcinoma of unknown primaryCarcinoma of unknown primary
Carcinoma of unknown primary
 
Bladder cancer
Bladder cancerBladder cancer
Bladder cancer
 

Dernier

Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxEduSkills OECD
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICESayali Powar
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?TechSoup
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphNetziValdelomar1
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesCeline George
 

Dernier (20)

Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptxPISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
PISA-VET launch_El Iza Mohamedou_19 March 2024.pptx
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICE
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?What is the Future of QuickBooks DeskTop?
What is the Future of QuickBooks DeskTop?
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a Paragraph
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 Sales
 

Thrombophilias

  • 2.
  • 3. Abnormal Blood Flow Abnormal Vessel Wall Dr. Rudolph Virchow 1821-1902 The Hypercoagulable State Abnormal Blood
  • 4. Thrombosis Hereditary thrombophilia Acquired thrombophilia Surgery trauma Immobility Inflammation Malignancy Estrogens Atherosclerosis
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.  
  • 10.
  • 11.
  • 12.
  • 13.
  • 14. FXI FIX FXII FV FVII Prothrombin Thrombin Fibrinogen Fibrin Clot FVIII FX
  • 16.
  • 17.
  • 18.  
  • 19.  
  • 20.  
  • 21.  
  • 22.  
  • 23.  
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.  
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.  
  • 35.
  • 36.
  • 38.  
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 52.
  • 53. .
  • 54.
  • 55.
  • 56. Sequelae Incidence Thrombosis 30%–50% Amputation 20% (arterial thrombosis) Death 22% to 28% .
  • 57.
  • 58. HIT Temporal Variants Day 1 Day 4 Day 14 Day 30 Delayed-onset HIT (9–40 days) Rapid-onset HIT (hours–days) Typical HIT Mean Day 9 (5–14 days) Heparin (re) Exposure THROMBOCYTOPENIA (± THROMBOSIS)
  • 59.
  • 60.
  • 61.
  • 62.
  • 63. Drug Indications Argatroban FDA-approved for HIT (also for PCI) Lepirudin FDA-approved for HIT Bivalirudin (Angiomax) PCI (including HIT patients) Fondaparinux (Arixtra) FDA approved for DVT Prophylaxis in patients with Hip#, Hip or knee replacements. Also used in Rx of VTE. Not yet approved for HIT (Off-label use) Danaparoid Approved for HIT in Canada, Europe, Aust.
  • 64.
  • 65. HIT Patients HIT Patients with Renal Impairment HIT Patients with Hepatic Impairment * Not to exceed a dose of 10 µg/kg/min or aPTT of 100 seconds † Due to approximate 4-fold decrease in Argatroban clearance relative to those with normal hepatic function Initiate at 2 µg/kg/min Titrate until steady-state aPTT is 1.5–3.0 times baseline value* No dosage adjustment required Initiate at 0.5 µg/kg/min † Titrate until steady-state aPTT is 1.5–3.0 times baseline value*
  • 66.
  • 67. If INR is below the therapeutic range for warfarin alone, resume Argatroban therapy If INR is >4.0, stop Argatroban infusion Initiate warfarin therapy using the expected daily dose of warfarin while maintaining Argatroban infusion. * A loading dose of warfarin should not be used If INR is within therapeutic range on warfarin alone, continue warfarin monotherapy If INR is  4.0, continue concomitant therapy Repeat INR 4-6 hours later Measure INR daily * For Argatroban infusion at  2 µg/kg/min, the INR on monotherapy may be estimated from the INR on cotherapy. If the dose of Argatroban >2  g/kg/min, temporarily reduce to a dose of 2  g/kg/min 4-6 hours prior to measuring the INR.  
  • 68.

Notes de l'éditeur

  1. Heterozygosity is about 5%. Homozygosity of leiden is 1% APC resistance often due to factor V leiden but it can occur due to other mutations in factor V. Acquired APC resistance can be seen in pregnancy.
  2. Heparin-Induced Thrombocytopenia (HIT): An Overview Key Point: Broad overview of what the presentation will discuss in detail. The anticoagulant heparin is used in more than 12 million patients per year 1 for treating and preventing thromboembolic disorders in medical and surgical patients. 2 Its importance as an anticoagulant has been well established by its effectiveness, rapid onset of action, ease of laboratory monitoring, and cost. Heparin can cause 2 forms of thrombocytopenia. This slide kit is primarily concerned with immune-mediated thrombocytopenia, or HIT, which occurs in up to 1% to 3% of patients receiving unfractionated heparin and in up to 2% of patients undergoing orthopedic surgery receiving low molecular weight heparin (LMWH). 2 HIT is a serious condition with about 50% of patients at risk of life- or limb-threatening thromboses if they remain untreated. 3 All forms of heparin should be discontinued in the presence of HIT. 4,5 An alternate anticoagulant should be strongly considered to treat HIT as well as the underlying condition. The Food and Drug Administration (FDA) has approved 2 anticoagulants for use in patients with HIT, lepirudin and argatroban. 1. Fahey VA. Heparin-induced thrombocytopenia. J Vasc Nurs . 1995;13(4):112-116. 2. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low- molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335. 3. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502-507. 4. Warkentin TE, Barkin RL. Newer strategies for the treatment of heparin- induced thrombocytopenia. Pharmacotherapy. 1999;19(2):181-195. 5. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol. 1995;89(3):431-439.
  3. HIT is an immune disease resulting in an extremely pro thrombotic state. HIT occurs due to presence of IgG antibodies that recognize heparin-PF4 complexes. Initially, Platelet activation leads to release of platelet factor 4 (PF4) and microparticles. The heparin that is administered forms complexes with PF4  the IgG antibodies that are already present ( from prior sensitization or from de novo formation during this exposure) now react with PF4-heparin complexes to form circulating immune complexes (PF4-heparin-IgG) which then bind to Fc receptors on the platelets thereby, activating the platelets further  leading to further release of microparticles and more PF4 and activation of the coagulation pathways through platelet-derived microparticles thus setting off prothrombotic state
  4. HIT is classified as two types HIT Type 1 which is non immune mild TP ( &gt;100k) associated with heparin that occurs with in first five days of heparin. This is not associated with thrombosis or antibody formation and platelet count recovers despite continuing Heparin. This is probably secondary to tiny platelet aggregates.
  5. 30 – 50% of patients presenting with HIT experience a thrombotic event within 30 days. Morbidity and mortality are significant in patients with HIT despite discontinuation of heparin therapy. Death can occur in 30% cases if untreated.
  6. Venous complications were observed more frequently than arterial events in a ratio of approximately 4:1. 3 The early symptoms of venous thrombosis may not be obvious. The most common venous thrombotic complication was deep vein thrombosis, which was responsible for more than 60% of thrombotic events in one study, followed by pulmonary embolism, which was responsible for 25% of all events. 3, 11 Arterial events are generally evidenced by overt clinical symptoms and may be life or limb threatening. In a single patient, significant clot extensions or multiple sites of thrombosis may occur. 5, 15
  7. HIT can be of 3 types based on the time of onset. Early onset HIT can occur with in 5 days of heparin re-exposure and is due to pre-existing circulating anti-PF4 antibodies due to prior recent exposure to heparin in the past 3 months ( the antibodies can exist up to 90 days after initial exposure to heparin). Typical HIT occurs between 5 to 14 days after exposure to heparin. Some patients may have delayed onset HIT which can start as late as 9 days after exposure to heparin and may occur until 40 days after exposure. HIT can occur up until 30 days even after stopping heparin due to circulating antibodies.
  8. HIT is a clinical diagnosis. Pre-test probabilty must be estimated by using 4T score. Most laboratory tests have long turnaround time and hence, therapy must not be delayed if pretest is high or intermediate.
  9. While these tests are helpful in confirming HIT, the diagnosis remains a clinical one since there is wide variability of, access to, and turnaround time for these assays. There is wide variability in sensitivity and specificity. If SRA is only 95% sensitive, a negative SRA will nor rule out HIT if clinical
  10. Direct Thrombin inhibitors : argatroban, lepirudin, bivalirudin. Fondaparinux : Is a INDIRECT inhibitor of Factor Xa. ( does not belong to class of direct thrombin inhibitors) The combination of once-daily subcutaneous administration, predictability of response, and minimal adverse effects makes fondaparinux an appealing alternative anticoagulant for patients with HIT. Although clinical experience with this agent in the setting of HIT is limited, the successful use of fondaparinux in patients with HIT has been reported. To date, one multicenter, blinded, comparative, in vitro study has demon-strated a lack of cross-reactivity between fondaparinux and HIT antibodies. At this time, use of fondaparinux in the setting of HIT is not recommended by the American College of Chest Physicians. Rather, the direct thrombin inhibitors lepirudin and argatroban are recommended as first-line agents. Nevertheless, limited clinical experience suggests that fondaparinux may be an alternative for anticoagulation in patients with HIT. Large, in vivo comparison trials must be performed before fondaparinux can become a standard treatment option in the setting of HIT
  11. Dosing for Argatroban is relatively straightforward. 17 The initial dose of Argatroban is 2  g/kg/min; the mean dose during clinical studies was 2  g/kg/min, indicating dose titration for many patients may not be necessary to achieve adequate anticoagulation. No dosage adjustment is necessary in patients with renal impairment. For patients with hepatic impairment, the dose should be reduced to 0.5  g/kg/min.
  12. If argatroban infusion rate is &gt;2mcg/kg/min  reduce dose to &lt;2mcg/kg/min first and then, measure inr after 4 hours – now, if INR &gt; 4, can stop argatroban